Dermira, Inc. is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil. Cimzia is an injectable biologic tumor necrosis factor-alpha inhibitor, or TNF inhibitor that is approved and marketed for the treatment of numerous inflammatory diseases spanning multiple medical specialties, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and Crohn's disease, in multiple countries, including the United States. Glycopyrronium tosylate is a small molecule anticholinergic product for topical application for the treatment of primary axillary hyperhidrosis. Olumacostat glasaretil is a small molecule that targets sebum production following topical application for the treatment of acne.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:DERM
- CUSIP: N/A
- Web: www.dermira.com
Capitalization:- Market Cap: $1.1875 billion
- Outstanding Shares: 41,521,000
Average Prices:- 50 Day Moving Avg: $28.99
- 200 Day Moving Avg: $31.12
- 52 Week Range: $25.63 - $38.75
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -8.83
- P/E Growth: -0.06
Sales & Book Value:- Annual Revenue: $23.65 million
- Price / Sales: 51.62
- Book Value: $9.76 per share
- Price / Book: 3.01
Profitability:- EBIDTA: ($91,810,000.00)
- Return on Equity: -30.71%
- Return on Assets: -26.01%
Debt:- Current Ratio: 20.33%
- Quick Ratio: 20.33%
Misc:- Average Volume: 521,462 shs.
- Beta: 0.84
- Short Ratio: 5.73
Frequently Asked Questions for Dermira (NASDAQ:DERM)
What is Dermira's stock symbol?
Dermira trades on the NASDAQ under the ticker symbol "DERM."
How were Dermira's earnings last quarter?
Dermira, Inc. (NASDAQ:DERM) posted its quarterly earnings results on Monday, November, 7th. The company reported ($0.72) earnings per share for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.72). The company had revenue of $0.12 million for the quarter. View Dermira's Earnings History.
Where is Dermira's stock going? Where will Dermira's stock price be in 2017?
9 brokerages have issued twelve-month price objectives for Dermira's stock. Their forecasts range from $40.00 to $48.00. On average, they anticipate Dermira's share price to reach $43.80 in the next twelve months. View Analyst Ratings for Dermira.
What are analysts saying about Dermira stock?
Here are some recent quotes from research analysts about Dermira stock:
- 1. Guggenheim analysts commented, "4Q16 results underscore that DERM continues to advance its pipeline of drugs that address large unmet needs in dermatology. Positive clinical data for DRM01 and DRM04 as well as solid execution in 4Q16, give us greater conviction in our positive investment thesis for the stock. We continue to think stock price appreciation will be driven by upward consensus earnings revisions to DERM's pipeline drug sales. We also view DERM as an attractive company in a consolidating industry." (3/2/2017)
- 2. According to Zacks Investment Research, "Dermira, Inc. is a specialty biopharmaceutical company. It is focused on bringing medical dermatology products to dermatologists and their patients. The Company markets topical small molecule therapeutics that target acne, sebaceous gland hyperactivity, and inflammatory skin diseases. Its late-stage product candidates comprise Cimzia which has completed Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; DRM04 that is in a Phase IIb clinical trial for the treatment of hyperhidrosis or excessive sweating; and DRM01 which has completed a Phase IIa clinical trial for the treatment of acne. Dermira, Inc. is headquartered in Redwood City, California. " (1/10/2017)
Who are some of Dermira's key competitors?
Some companies that are related to Dermira include Axovant Sciences (AXON), AveXis (AVXS), Spark Therapeutics (ONCE), Aerie Pharmaceuticals (AERI), Loxo Oncology (LOXO), Halozyme Therapeutics (HALO), Radius Health (RDUS), Lexicon Pharmaceuticals (LXRX), NovoCure Limited (NVCR), Array BioPharma (ARRY), Acceleron Pharma (XLRN), Amarin Corporation PLC (AMRN), Clinigen Group PLC (CLIN), Xencor (XNCR), Insmed (INSM), Forward Pharma A/S (FWP), Acorda Therapeutics (ACOR) and Synergy Pharmaceuticals (SGYP).
Who are Dermira's key executives?
Dermira's management team includes the folowing people:
- Thomas G. Wiggans, Chairman of the Board, Chief Executive Officer, Co-Founder
- William D. Young, Chairman of the Board
- Christopher M. Griffith, Senior Vice President - Corporate Development and Strategy, Founder
- Luis C. Pena, Co-Founder, Chief Development Officer
- Andrew L. Guggenhime, Chief Financial Officer, Chief Operating Officer
- Lori Lyons-Williams, Chief Commercial Officer
- Eugene A. Bauer M.D., Founder, Chief Medical Officer, Director
- Frederick B. Craves Ph.D., Lead Director, Independent Director
- Emmanuel Caeymaex, Director
- David E. Cohen M.D., Independent Director
How do I buy Dermira stock?
Shares of Dermira can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Dermira's stock price today?
One share of Dermira stock can currently be purchased for approximately $29.40.
MarketBeat Community Rating for Dermira (NASDAQ DERM)MarketBeat's community ratings are surveys of what our community members think about Dermira and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Dermira (NASDAQ:DERM) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 3 Sell Ratings, 6 Buy Ratings |
| Consensus Rating: | Hold (Score: 2.33) |
| Consensus Price Target: | $43.80 (48.98% upside) |
Analysts' Ratings History for Dermira (NASDAQ:DERM)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 7/18/2017 | Needham & Company LLC | Reiterated Rating | Buy | $46.00 | Low |  |
| 6/29/2017 | Evercore ISI | Initiated Coverage | Outperform | $48.00 | Medium | |
| 6/22/2017 | Cantor Fitzgerald | Initiated Coverage | Overweight | $45.00 | Medium | |
| 5/25/2017 | Mizuho | Lower Price Target | Buy -> Buy | $42.00 -> $40.00 | Low | |
| 3/16/2017 | Raymond James Financial, Inc. | Initiated Coverage | Underperform -> Underperform | | High | |
| 3/15/2017 | Citigroup Inc. | Initiated Coverage | Underperform | | High | |
| 3/2/2017 | Guggenheim | Reiterated Rating | Buy -> Positive | $40.00 | N/A | |
| 1/3/2017 | SEB Equity Research | Reiterated Rating | Reduce | | N/A | |
| 10/5/2016 | Leerink Swann | Reiterated Rating | Buy | | N/A | |
| 6/2/2016 | Wedbush | Boost Price Target | Outperform | $42.00 -> $46.00 | N/A | |
| 8/19/2015 | Cowen and Company | Initiated Coverage | Outperform | $40.00 | N/A | |
(Data available from 7/22/2015 forward)
Earnings History for Dermira (NASDAQ:DERM)Earnings History by Quarter for Dermira (NASDAQ DERM)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 2/28/2017 | Q4 2016 | ($0.93) | ($0.21) | | $22.47 million | View | Listen | |
| 11/7/2016 | Q316 | ($0.72) | ($0.72) | | $0.12 million | View | N/A | |
| 8/8/2016 | Q2 | ($0.86) | ($0.89) | | | View | N/A | |
| 5/10/2016 | Q1 | ($0.94) | ($0.95) | | | View | Listen | |
| 11/10/2015 | Q3 | ($0.77) | ($0.58) | | $7.30 million | View | N/A | |
| 8/13/2015 | Q2 | ($0.81) | ($0.69) | | | View | N/A | |
| 5/12/2015 | Q1 | ($0.65) | ($0.57) | | | View | N/A | |
| 3/25/2015 | Q4 | ($0.59) | ($0.29) | | $7.30 million | View | Listen | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Dermira (NASDAQ:DERM)2017 EPS Consensus Estimate: ($3.88)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($0.84) | ($0.84) | ($0.84) |
| Q2 2017 | 1 | ($0.81) | ($0.81) | ($0.81) |
| Q3 2017 | 1 | ($1.00) | ($1.00) | ($1.00) |
| Q4 2017 | 1 | ($1.23) | ($1.23) | ($1.23) |
(Data provided by Zacks Investment Research)
Dividend History for Dermira (NASDAQ:DERM)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Dermira (NASDAQ:DERM)Insider Ownership Percentage: 13.30%
Institutional Ownership Percentage: 84.58%
Insider Trades by Quarter for Dermira (NASDAQ:DERM)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 7/5/2017 | Eugene A Bauer | Insider | Sell | 2,500 | $30.00 | $75,000.00 | |
| 7/3/2017 | Thomas G. Wiggans | CEO | Sell | 5,000 | $29.06 | $145,300.00 | |
| 6/20/2017 | Eugene A Bauer | Insider | Sell | 2,500 | $30.01 | $75,025.00 | |
| 6/2/2017 | Thomas G. Wiggans | CEO | Sell | 5,000 | $27.52 | $137,600.00 | |
| 5/15/2017 | Christopher M. Griffith | SVP | Sell | 1,312 | $27.07 | $35,515.84 | |
| 4/17/2017 | Christopher M. Griffith | SVP | Sell | 1,303 | $33.97 | $44,262.91 | |
| 4/3/2017 | Eugene A Bauer | Insider | Sell | 2,500 | $33.53 | $83,825.00 | |
| 4/3/2017 | Thomas G Wiggans | CEO | Sell | 8,000 | $33.49 | $267,920.00 | |
| 4/3/2017 | William R Ringo | Director | Sell | 500 | $34.03 | $17,015.00 | |
| 3/15/2017 | Christopher M. Griffith | SVP | Sell | 1,303 | $35.79 | $46,634.37 | |
| 3/1/2017 | Eugene A Bauer | Insider | Sell | 2,500 | $33.61 | $84,025.00 | |
| 3/1/2017 | Thomas G Wiggans | CEO | Sell | 11,000 | $33.54 | $368,940.00 | |
| 3/1/2017 | William R Ringo | Director | Sell | 500 | $35.09 | $17,545.00 | |
| 2/15/2017 | Christopher M. Griffith | SVP | Sell | 1,303 | $30.79 | $40,119.37 | |
| 2/15/2017 | William R Ringo | Director | Sell | 500 | $32.00 | $16,000.00 | |
| 2/14/2017 | Eugene A Bauer | Insider | Sell | 1,505 | $30.00 | $45,150.00 | |
| 2/1/2017 | Eugene A Bauer | Insider | Sell | 995 | $30.00 | $29,850.00 | |
| 1/17/2017 | Christopher M. Griffith | VP | Sell | 1,303 | $29.11 | $37,930.33 | |
| 1/4/2017 | Thomas G Wiggans | CEO | Sell | 8,000 | $31.06 | $248,480.00 | |
| 1/4/2017 | William R Ringo | Director | Sell | 500 | $32.00 | $16,000.00 | |
| 1/3/2017 | Eugene A Bauer | Insider | Sell | 2,500 | $30.07 | $75,175.00 | |
| 12/16/2016 | William R Ringo | Director | Sell | 125 | $32.00 | $4,000.00 | |
| 12/15/2016 | Christopher M. Griffith | VP | Sell | 1,303 | $30.70 | $40,002.10 | |
| 12/14/2016 | Eugene A Bauer | Insider | Sell | 2,500 | $30.36 | $75,900.00 | |
| 12/1/2016 | Thomas G Wiggans | CEO | Sell | 11,000 | $30.80 | $338,800.00 | |
| 12/1/2016 | William R Ringo | Director | Sell | 375 | $32.00 | $12,000.00 | |
| 11/9/2016 | Andrew Guggenhime | CFO | Sell | 4,100 | $35.02 | $143,582.00 | |
| 11/9/2016 | William R Ringo | Director | Sell | 500 | $32.30 | $16,150.00 | |
| 11/1/2016 | Thomas G Wiggans | CEO | Sell | 11,000 | $31.19 | $343,090.00 | |
| 10/17/2016 | Christopher M Griffith | VP | Sell | 1,303 | $32.33 | $42,125.99 | |
| 10/11/2016 | Andrew Guggenhime | CFO | Sell | 10,900 | $34.34 | $374,306.00 | |
| 10/3/2016 | Thomas G Wiggans | CEO | Sell | 11,000 | $34.60 | $380,600.00 | |
| 10/3/2016 | William R Ringo | Director | Sell | 500 | $34.25 | $17,125.00 | |
| 9/19/2016 | Andrew Guggenhime | CFO | Sell | 15,000 | $35.01 | $525,150.00 | |
| 9/15/2016 | Christopher M Griffith | VP | Sell | 1,303 | $33.26 | $43,337.78 | |
| 9/12/2016 | Andrew Guggenhime | CFO | Sell | 10,000 | $32.53 | $325,300.00 | |
| 9/1/2016 | Thomas G Wiggans | CEO | Sell | 11,000 | $31.63 | $347,930.00 | |
| 9/1/2016 | William R Ringo | Director | Sell | 500 | $32.00 | $16,000.00 | |
| 8/15/2016 | Christopher M Griffith | VP | Sell | 1,303 | $31.75 | $41,370.25 | |
| 8/11/2016 | Andrew Guggenhime | CFO | Sell | 10,000 | $31.02 | $310,200.00 | |
| 8/1/2016 | Eugene A Bauer | Insider | Sell | 2,500 | $33.18 | $82,950.00 | |
| 8/1/2016 | Thomas G Wiggans | CEO | Sell | 11,000 | $33.19 | $365,090.00 | |
| 8/1/2016 | William R Ringo | Director | Sell | 500 | $33.65 | $16,825.00 | |
| 7/15/2016 | Christopher M Griffith | VP | Sell | 1,303 | $30.02 | $39,116.06 | |
| 7/11/2016 | Andrew Guggenhime | CFO | Sell | 10,000 | $30.15 | $301,500.00 | |
| 7/5/2016 | Thomas G Wiggans | CEO | Sell | 11,000 | $29.62 | $325,820.00 | |
| 7/1/2016 | Eugene A Bauer | Insider | Sell | 2,500 | $29.48 | $73,700.00 | |
| 6/23/2016 | Luis C Pena | Insider | Sell | 10,000 | $30.01 | $300,100.00 | |
| 6/15/2016 | Luis C Pena | Insider | Sell | 10,000 | $29.47 | $294,700.00 | |
| 6/13/2016 | Christopher M Griffith | VP | Sell | 4,405 | $30.16 | $132,854.80 | |
| 6/1/2016 | Eugene A Bauer | Insider | Sell | 2,500 | $31.65 | $79,125.00 | |
| 6/1/2016 | Thomas G Wiggans | CEO | Sell | 11,000 | $31.57 | $347,270.00 | |
| 5/2/2016 | Eugene A Bauer | Insider | Sell | 2,500 | $25.09 | $62,725.00 | |
| 5/2/2016 | Thomas G Wiggans | CEO | Sell | 9,000 | $25.11 | $225,990.00 | |
| 4/1/2016 | Eugene A Bauer | Insider | Sell | 2,500 | $20.84 | $52,100.00 | |
| 4/1/2016 | Thomas G Wiggans | CEO | Sell | 7,000 | $20.69 | $144,830.00 | |
| 3/1/2016 | Eugene A Bauer | Insider | Sell | 2,500 | $22.55 | $56,375.00 | |
| 3/1/2016 | Thomas G Wiggans | CEO | Sell | 7,000 | $22.57 | $157,990.00 | |
| 2/1/2016 | Eugene A Bauer | Insider | Sell | 2,500 | $27.26 | $68,150.00 | |
| 2/1/2016 | Thomas G Wiggans | CEO | Sell | 9,000 | $27.25 | $245,250.00 | |
| 1/4/2016 | Eugene A Bauer | Insider | Sell | 2,500 | $33.17 | $82,925.00 | |
| 1/4/2016 | Thomas G Wiggans | CEO | Sell | 11,000 | $33.17 | $364,870.00 | |
| 12/1/2015 | Eugene A Bauer | Insider | Sell | 2,500 | $29.65 | $74,125.00 | |
| 11/2/2015 | Eugene A Bauer | Insider | Sell | 2,500 | $27.82 | $69,550.00 | |
| 10/1/2015 | Eugene A Bauer | Insider | Sell | 2,500 | $22.87 | $57,175.00 | |
| 9/14/2015 | Eugene A Bauer | Insider | Sell | 22,500 | $28.05 | $631,125.00 | |
| 11/25/2014 | Matthew K Fust | Director | Buy | 6,000 | $16.77 | $100,620.00 | |
| 10/8/2014 | Bay City Capital Llc | Director | Buy | 69,112 | $16.00 | $1,105,792.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Dermira (NASDAQ:DERM)
Latest Headlines for Dermira (NASDAQ:DERM)
| Source: |
|
| Date | Headline |
|---|
 | Dermira, Inc. breached its 50 day moving average in a Bearish Manner : DERM-US : July 21, 2017
finance.yahoo.com - July 21 at 7:35 PM |
 | Dermira, Inc. (NASDAQ:DERM) Given Buy Rating at Needham & Company LLC
www.americanbankingnews.com - July 18 at 1:18 PM |
| Dermira, Inc. (NASDAQ:DERM) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - July 17 at 12:33 PM |
| ETFs with exposure to Dermira, Inc. : July 14, 2017
finance.yahoo.com - July 14 at 3:45 PM |
| Dermira, Inc. – Value Analysis (NASDAQ:DERM) : July 12, 2017
finance.yahoo.com - July 12 at 6:28 PM |
| Dermira, Inc. breached its 50 day moving average in a Bearish Manner : DERM-US : July 11, 2017
finance.yahoo.com - July 11 at 6:58 PM |
| Dermira, Inc. (DERM) Insider Sells $75,000.00 in Stock
www.americanbankingnews.com - July 6 at 8:06 PM |
| Insider Selling: Dermira, Inc. (NASDAQ:DERM) CEO Sells 5,000 Shares of Stock
www.americanbankingnews.com - July 5 at 7:45 PM |
| Dermira, Inc. (NASDAQ:DERM) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - July 3 at 3:22 PM |
| Evercore ISI Begins Coverage on Dermira, Inc. (DERM)
www.americanbankingnews.com - June 29 at 6:42 PM |
 | Dermira (DERM) Reports Nonclinical Data Highlight the Role of Olumacostat Glasaretil in Sebum Inhibition
www.streetinsider.com - June 26 at 10:37 PM |
 | BRIEF-Dermira says findings from nonclinical studies evaluating mechanism of action for olumacostat glasaretil in sebum inhibition were published
www.reuters.com - June 26 at 10:37 PM |
| Newly Published Nonclinical Data Highlight the Role of Olumacostat Glasaretil in Sebum Inhibition
finance.yahoo.com - June 26 at 5:34 PM |
| Analysts Offer Predictions for Dermira, Inc.'s FY2017 Earnings (DERM)
www.americanbankingnews.com - June 26 at 7:41 AM |
| Dermira, Inc. (DERM) Now Covered by Cantor Fitzgerald
www.americanbankingnews.com - June 22 at 2:58 PM |
| Dermira, Inc. breached its 50 day moving average in a Bullish Manner : DERM-US : June 22, 2017
finance.yahoo.com - June 22 at 10:24 AM |
| Eugene A. Bauer Sells 2,500 Shares of Dermira, Inc. (DERM) Stock
www.americanbankingnews.com - June 21 at 8:04 PM |
| Dermira, Inc. (DERM) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - June 20 at 10:30 AM |
| Dermira, Inc. (DERM) Raised to Hold at BidaskClub
www.americanbankingnews.com - June 15 at 6:58 PM |
| Thomas G. Wiggans Sells 5,000 Shares of Dermira Inc (DERM) Stock
www.americanbankingnews.com - June 5 at 10:19 PM |
| Dermira to Present at Jefferies 2017 Global Healthcare Conference
finance.yahoo.com - May 30 at 4:38 PM |
| Short Interest in Dermira Inc (DERM) Grows By 66.8%
www.americanbankingnews.com - May 28 at 7:02 AM |
| Dermira Inc (DERM) PT Lowered to $40.00
www.americanbankingnews.com - May 27 at 12:58 AM |
| Dermira Inc (DERM) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - May 26 at 10:50 AM |
| Teva Pharma, Eagle Pharma, Depomed Among Slew Getting Price Haircuts
finance.yahoo.com - May 25 at 6:30 PM |
| Dermira Inc (DERM) Short Interest Up 2.9% in April
www.americanbankingnews.com - May 22 at 9:16 PM |
| DERMIRA, INC. (DERM)
finance.yahoo.com - May 16 at 9:43 PM |
| Insider Selling: Dermira Inc (DERM) SVP Sells 1,312 Shares of Stock
www.americanbankingnews.com - May 16 at 8:44 PM |
| Dermira Announces Closing of 3.00% Convertible Senior Notes Offering
finance.yahoo.com - May 16 at 4:42 PM |
| Dermira Inc (DERM) Expected to Earn Q2 2017 Earnings of ($0.81) Per Share
www.americanbankingnews.com - May 11 at 8:52 AM |
| Dermira Prices Offering of $250 Million of 3.00% Convertible Senior Notes
finance.yahoo.com - May 10 at 9:51 PM |
| Here's Why Dermira Fell as Much as 18.7% This Morning
finance.yahoo.com - May 10 at 4:51 PM |
| FY2020 EPS Estimates for Dermira Inc (DERM) Cut by Analyst
www.americanbankingnews.com - May 10 at 3:38 PM |
| Dermira Announces Proposed Offering of $250 Million of Convertible Senior Notes
finance.yahoo.com - May 9 at 4:41 PM |
| BRIEF-Dermira qtrly net loss per share, basic, diluted $ 0.79
www.reuters.com - May 9 at 5:43 AM |
 | Dermira Reports First Quarter 2017 Financial Results and Provides Corporate Update
www.nasdaq.com - May 9 at 5:43 AM |
 | Dermira reports 1Q loss
marketbeat.com - May 8 at 5:36 PM |
| Dermira Reports First Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - May 8 at 4:30 PM |
| Dermira (DERM) Earning Somewhat Favorable Media Coverage, Study Finds
www.americanbankingnews.com - May 1 at 5:44 PM |
| Dermira Inc (DERM) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - May 1 at 2:24 PM |
| Dermira Inc (DERM) Expected to Announce Earnings of -$0.86 Per Share
www.americanbankingnews.com - May 1 at 10:04 AM |
| Dermira (DERM) Earning Somewhat Negative News Coverage, Report Finds
www.americanbankingnews.com - April 28 at 10:26 AM |
| Dermira (DERM) Given Coverage Optimism Score of 0.12
www.americanbankingnews.com - April 25 at 7:30 PM |
| Dermira (DERM) Getting Favorable News Coverage, AlphaOne Reports
www.americanbankingnews.com - April 22 at 2:49 PM |
| Dermira, Inc. – Value Analysis (NASDAQ:DERM) : April 20, 2017
finance.yahoo.com - April 20 at 4:49 PM |
| Dermira, Inc. breached its 50 day moving average in a Bearish Manner : DERM-US : April 19, 2017
finance.yahoo.com - April 19 at 12:31 PM |
| Dermira (DERM) Getting Positive News Coverage, Study Shows
www.americanbankingnews.com - April 19 at 10:04 AM |
| Insider Selling: Dermira Inc (DERM) SVP Sells 1,303 Shares of Stock
www.americanbankingnews.com - April 18 at 10:59 PM |
| Dermira (DERM) Earns Media Impact Rating of 0.30
www.americanbankingnews.com - April 16 at 9:08 AM |
| Dermira Inc (DERM) Expected to Post Earnings of -$0.86 Per Share
www.americanbankingnews.com - April 10 at 12:13 PM |
Dermira (DERM) Chart for Saturday, July, 22, 2017
